Sort   by:  
 Page size 
MetabolomicsCreatine uptake promotes dendritic cell activation and enhances antitumor immunity

Dendritic cells (DCs) are central regulators of antitumor T cell immunity and are highly sensitive to metabolic cues. However, the therapeutic potential of targeting DC metabolism remains underexplored. Here, we report upregulation of the creatine transporter (CrT; Slc6a8) in intratumora...

2026-03-11 | MTBLS12797 | MetaboLights
MetabolomicsPolyamines regulate adaptive antitumor immunity by functional specialization of regulatory T cells

In cancer, metabolic changes and uncontrolled tumor growth alter nutrient availability, impacting antitumor immune responses. Regulatory T (Treg) cells are a subset of T cells with immunosuppressive properties that has been found to additionally possess the ability to control tissue homeostasis a...

2025-07-24 | MTBLS12633 | MetaboLights
MetabolomicsCeramide Disrupts TM9SF2-PGK1 Axis to Redirect PD-L1 Trafficking and Enhance Antitumor Immunity

The PD-1/PD-L1 axis represents a cornerstone of cancer immunotherapy, yet the dynamic shuttling of PD-L1 between endosomal recycling and lysosomal degradation routes limits durable responses. Using a CRISPR screen targeting glycosphingolipid metabolism, we identify TM9SF2 as a key regulator of PD...

2026-02-05 | MTBLS13838 | MetaboLights
MetabolomicsNano-hijacked myeloid cells potentiate antitumor immunity and radiotherapy for glioblastoma
Not available
ORGANISM(S): Mus musculus 
ST002467 | MetabolomicsWorkbench
MetabolomicsGut Microbiota-Mediated Tryptophan Metabolism Plays Dual Effects in Diffuse Large B-Cell Lymphoma via Regulating 3-IAA/5-HTP Balance and Antitumor Immunity
Timing-dependent tryptophan diets differentially modulate DLBCL outcomes via microbiota-derived 3-IAA (pre-inoculation, anti-tumor) versus 5-HTP (post-inoculation, pro-tumor), with pectin restoring microbial balance to enable a timed tryptophan-pectin precision nutrition strategy for enhanced immuno...
2026-09-07 | MTBLS15570 | MetaboLights
ProteomicsNATCANCER-A16341B 1 2 iNV GOV 3 4GOV
Oncolytic viruses (OVs) are replication-competent viruses that selectively infect tumor cells and induce anti-tumor responses. However, systemic delivery is limited by neutralizing antibodies and poor intratumoral bioavailability. We developed iNV-GOV, a tumor-targeted, low-immunogenic platform that...
ORGANISM(S): Homo sapiens (Human) 
2025-10-03 | PXD067837 | Pride
Inv gov and gov 
GenomicsSETDB1-TRIM28 complex suppresses antitumor immunity [RNA-seq]
SETDB1-TRIM28 complex suppresses antitumor immunity [RNA-seq]
PRJNA754434 | ENA
ProteomicsCeramide Disrupts TM9SF2-PGK1 Axis to Redirect PD-L1 Trafficking and Enhance Antitumor Immunity
The programmed cell death protein 1 (PD-1) / programmed death-ligand 1 (PD-L1) axis represents a cornerstone of cancer immunotherapy, yet the dynamic shuttling of PD-L1 between endosomal recycling and lysosomal degradation routes limits durable responses. Using a CRISPR screen targeting glycosphingo...
ORGANISM(S): Homo Sapiens 
2026-02-27 | PXD075012 |
ProteomicsTargeting LRBA triggers CTLA4 degradation and antitumor immunity for cancer immunotherapy
The lipopolysaccharide-responsive beige-like anchor protein (LRBA) deficiency causes severe autoimmune diseases and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) loss in humans. However, the impact of LRBA on antitumor immunity remains understudied. Here, we identified the role of LRBA in anti...
ORGANISM(S): Mus musculus (Mouse) 
2026-01-23 | PXD064363 | Pride
GenomicsSETDB1-TRIM28 complex suppresses antitumor immunity [CRISPR/Cas9 screen]
SETDB1-TRIM28 complex suppresses antitumor immunity [CRISPR/Cas9 screen]
PRJNA755293 | ENA
Sort   by:  
 Page size